{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:29:44Z","timestamp":1770352184872,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2679,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1097\/jto.0b013e318180275e","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T01:06:37Z","timestamp":1264554397000},"page":"912-914","source":"Crossref","is-referenced-by-count":33,"title":["Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to Gefitinib"],"prefix":"10.1016","volume":"3","author":[{"given":"Enrico","family":"Vasile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Tibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Chella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e318180275e_bib1","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318180275e_bib2","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1097\/JTO.0b013e318180275e_bib3","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318180275e_bib4","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e318180275e_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e318180275e_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1634\/theoncologist.10-7-467","article-title":"The current situation: Erlotinib (Tarceva\u00ae) and Gefitinib (Iressa\u00ae) in non-small cell lung cancer","volume":"10","author":"Comis","year":"2005","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e318180275e_bib7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e318180275e_bib8","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2006.10.4166","article-title":"Phase II study of Erlotinib in advanced non-small cell lung cancer after failure of Gefitinib","volume":"25","author":"Cho","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318180275e_bib9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/JTO.0b013e3180cc25b0","article-title":"Three cases of long-lasting tumor control with Erlotinib after progression with Gefitinib in advanced non-small cell lung cancer","volume":"2","author":"Gridelli","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e318180275e_bib10","doi-asserted-by":"crossref","first-page":"7738","DOI":"10.1200\/JCO.2005.02.4471","article-title":"Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung cancer","volume":"23","author":"Garfield","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318180275e_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.lungcan.2005.07.004","article-title":"Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer","volume":"50","author":"Viswanathan","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e318180275e_bib12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.clon.2006.07.002","article-title":"Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash","volume":"18","author":"Walther","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1097\/JTO.0b013e318180275e_bib13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.lungcan.2007.05.018","article-title":"Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer","volume":"58","author":"Chang","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e318180275e_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/ncponc0400","article-title":"Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation","volume":"3","author":"Choong","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1097\/JTO.0b013e318180275e_bib15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/JTO.0b013e318168c801","article-title":"Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer","volume":"3","author":"Wong","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"suppl 4","key":"10.1097\/JTO.0b013e318180275e_bib16","doi-asserted-by":"crossref","first-page":"S739","DOI":"10.1097\/01.JTO.0000284115.28337.39","article-title":"Erlotinib treatment after progression on gefitinib in non-small cell lung cancer (NSCLC)","volume":"8","author":"Sim","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"suppl 4","key":"10.1097\/JTO.0b013e318180275e_bib17","doi-asserted-by":"crossref","first-page":"S743","DOI":"10.1097\/01.JTO.0000284125.66454.16","article-title":"Phase II study of erlotinib in patients with advanced non-small cell lung cancer who failed prior gefitinib treatment","volume":"8","author":"Shih","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"suppl 4","key":"10.1097\/JTO.0b013e318180275e_bib18","doi-asserted-by":"crossref","first-page":"S716","DOI":"10.1097\/01.JTO.0000284065.60731.2c","article-title":"Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC)","volume":"8","author":"Grossi","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"suppl 4","key":"10.1097\/JTO.0b013e318180275e_bib19","doi-asserted-by":"crossref","first-page":"S545","DOI":"10.1097\/01.JTO.0000283602.16598.54","article-title":"Disruption of a conserved ion pair E884-R958 in EGFR differentially alters kinase inhibitor sensitivity and downstream signalling","volume":"8","author":"Tang","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e318180275e_bib20","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-07-0560","article-title":"Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus","volume":"13","author":"Riley","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415304573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415304573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T07:00:28Z","timestamp":1558767628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415304573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S1556086415304573"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e318180275e","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}